Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of Infliximab in Inflammatory Bowel Disease
2011-001332-29Phase 4Completed
- Sponsor
- Medical University of Vienna, Department of Internal Medicine IV
- Start
- Nov 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of infliximab in Crohn's disease, autoimmune colitis and inflammatory bowel disease (IBD), sponsored by Medical University of Vienna, Department of Internal Medicine IV. Primary endpoint: Serum infliximab level difference vs prediction at week 4. Started Nov 2013; status: completed.
02
Drugs
infliximab
03
Conditions
Crohn's diseaseautoimmune colitisinflammatory bowel disease (IBD)
Beyond the preview
Go deeper on 2011-001332-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-001332-29.